D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 6, 2012, Pages 263-272

  Smee, Donald F ^a   Hurst, Brett L ^a   Day, Craig W ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BUTYLPHENYL)AMINO] 2 METHYLENE 4 OXO BUTANOIC ACID; ANTIVIRUS AGENT; CYTIDINE; DIHYDROOROTATE DEHYDROGENASE; ENZYME INHIBITOR; OROTIC ACID; PYRIMIDINE; RIBAVIRIN; UNCLASSIFIED DRUG; URIDINE; URIDINE TRIPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MICHAELIS CONSTANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN;

ANILIDES; ANIMALS; ANTIVIRAL AGENTS; BUTYRIC ACID; DOGS; FEMALE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; LIVER; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; OROTIC ACID; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRIMIDINES; SUCCINATES;

EID: 84871304230     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2105     Document Type: Article

References (43)

1. Besselaar TG, Naidoo D, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008; 14:1809-1810.
2. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
3. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-560.
4. Mossad SB. The resurgence of swine-origin influenza A (H1N1). Cleve Clin J Med 2009; 76:337-343.
5. Adams S, Sandrock C. Avian influenza: update. Med Princ Pract 2010; 19:421-432.
6. Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 2011; 9:851-857.
7. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-986.
8. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977-981.
9. Takahashi K, Furuta Y, Fukuda Y, et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 2003; 14:235-241.
10. Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51:845-851.
11. Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antiviral Res 2011; 90:17-21.
12. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010; 5:e9332.
13. Duque MD, Ma C, Torres E, et al. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J Med Chem 2011; 54:2646-2657.
14. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 2011; 108:5777-5782.
15. Maddry JA, Chen X, Jonsson CB, et al. Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen. J Biomol Screen 2011; 16:73-81.
16. Hsu JT, Yeh JY, Lin TJ, et al. Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus. Antimicrob Agents Chemother 2012; 56:647-657.
17. Shih SR, Chu TY, Reddy GR, et al. Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity. J Biomed Sci 2010; 17:13.
18. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001; 45:743-748.
19. Smee DF, Morrison AC, Barnard DL, Sidwell RW. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Methods 2002; 106:71-79.
20. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493-498.
21. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 2009; 64:741-746.
22. Smee DF, Humphreys DE, Hurst BL, Barnard DL. Antiviral activities and phosphorylation of 5-halo-2′-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus. Antivir Chem Chemother 2008; 19:15-24.
23. Smee DF, Matthews TR. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob Agents Chemother 1986; 30:117-121.
24. Peters GJ, Laurensse E, Leyva A, Pinedo HM. A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography. Anal Biochem 1987; 161:32-38.
25. Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22:3099-3108.
26. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003; 58:73-79.
27. Smee DF, McKernan PA, Nord LD, et al. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob Agents Chemother 1987; 31:1535-1541.
28. Dunn MC, Knight DA, Waldman WJ. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 2011; 16:309-317.
29. Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol 2010; 84:2150-2156.
30. Williams CR, Sykes JE, Mehl M, et al. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1. Am J Vet Res 2007; 68:1010-1015.
31. Wang QY, Bushell S, Qing M, et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011; 85:6548-6556.
32. Chon WJ, Josephson MA. Leflunomide in renal transplantation. Expert Rev Clin Immunol 2011; 7:273-281.
33. Wang TY, Li J, Li CY, et al. Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells. Can J Physiol Pharmacol 2010; 88:45-53.
34. Mor E, Yussim A, Chodoff L, Schwartz ME. New immunosuppressive agents for maintenance therapy in organ transplantation. BioDrugs 1997; 8:469-488.
35. Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010; 90:1450-1457.
36. Steffenhagen KA, Easterday BC, Galasso GJ. Evaluation of 6-azauridine and 5-iododeoxyuridine in the treatment of experimental viral infections. J Infect Dis 1976; 133:603-612.
37. Davis IC, Lazarowski ER, Chen FP, Hickman-Davis JM, Sullender WM, Matalon S. Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection. Am J Respir Cell Mol Biol 2007; 37:379-386.
38. Zhang C, Xu Y, Jia L, et al. A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J 2010; 7:30.
39. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 2003; 36:290-294.
40. Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J Infect Dis 2004; 190:1132-1139.
41. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993; 41:242-246.
42. Schnellrath LC, Damasco CR. Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture. Int J Antimicrob Agents 2011; 38:435-441.
43. Barnard DL. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 2009; 82:A110-A122.